BACKGROUND: Superinfections, including invasive pulmonary aspergillosis (IPA), are well-known complications of critically ill patients with severe viral pneumonia. Aim of this study was to evaluate the incidence, risk factors and outcome of IPA in critically ill patients with severe COVID-19 pneumonia. METHODS: We prospectively screened 32 critically ill patients with severe COVID-19 pneumonia for a time period of 28 days using a standardized study protocol for oberservation of developement of COVID-19 associated invasive pulmonary aspergillosis (CAPA). We collected laboratory, microbiological, virological and clinical parameters at defined timepoints in combination with galactomannan-antigen-detection from nondirected bronchial lavage (NBL). We used logistic regression analyses to assess if COVID-19 was independently associated with IPA and compared it with matched controls. FINDINGS: CAPA was diagnosed at a median of 4 days after ICU admission in 11/32 (34%) of critically ill patients with severe COVID-19 pneumonia as compared to 8% in the control cohort. In the COVID-19 cohort, mean age, APACHE II score and ICU mortality were higher in patients with CAPA than in patients without CAPA (36% versus 9.5%; p<0.001). ICU stay (21 versus 17 days; p = 0.340) and days of mechanical ventilation (20 versus 15 days; p = 0.570) were not different between both groups. In regression analysis COVID-19 and APACHE II score were independently associated with IPA. INTERPRETATION: CAPA is highly prevalent and associated with a high mortality rate. COVID-19 is independently associated with invasive pulmonary aspergillosis. A standardized screening and diagnostic approach as presented in our study can help to identify affected patients at an early stage.
BACKGROUND: Superinfections, including invasive pulmonary aspergillosis (IPA), are well-known complications of critically illpatients with severe viral pneumonia. Aim of this study was to evaluate the incidence, risk factors and outcome of IPA in critically illpatients with severe COVID-19 pneumonia. METHODS: We prospectively screened 32 critically illpatients with severe COVID-19 pneumonia for a time period of 28 days using a standardized study protocol for oberservation of developement of COVID-19 associated invasive pulmonary aspergillosis (CAPA). We collected laboratory, microbiological, virological and clinical parameters at defined timepoints in combination with galactomannan-antigen-detection from nondirected bronchial lavage (NBL). We used logistic regression analyses to assess if COVID-19 was independently associated with IPA and compared it with matched controls. FINDINGS: CAPA was diagnosed at a median of 4 days after ICU admission in 11/32 (34%) of critically illpatients with severe COVID-19 pneumonia as compared to 8% in the control cohort. In the COVID-19 cohort, mean age, APACHE II score and ICU mortality were higher in patients with CAPA than in patients without CAPA (36% versus 9.5%; p<0.001). ICU stay (21 versus 17 days; p = 0.340) and days of mechanical ventilation (20 versus 15 days; p = 0.570) were not different between both groups. In regression analysis COVID-19 and APACHE II score were independently associated with IPA. INTERPRETATION: CAPA is highly prevalent and associated with a high mortality rate. COVID-19 is independently associated with invasive pulmonary aspergillosis. A standardized screening and diagnostic approach as presented in our study can help to identify affected patients at an early stage.
Authors: Frank L van de Veerdonk; Eva Kolwijck; Pieter P A Lestrade; Caspar J Hodiamont; Bart J A Rijnders; Judith van Paassen; Pieter-Jan Haas; Claudy Oliveira Dos Santos; Greetje A Kampinga; Dennis C J J Bergmans; Karin van Dijk; Anton F J de Haan; Jaap van Dissel; Hans G van der Hoeven; Paul E Verweij Journal: Am J Respir Crit Care Med Date: 2017-04-07 Impact factor: 21.405
Authors: Stijn I Blot; Fabio Silvio Taccone; Anne-Marie Van den Abeele; Pierre Bulpa; Wouter Meersseman; Nele Brusselaers; George Dimopoulos; José A Paiva; Benoit Misset; Jordi Rello; Koenraad Vandewoude; Dirk Vogelaers Journal: Am J Respir Crit Care Med Date: 2012-04-19 Impact factor: 21.405
Authors: Alexander F A D Schauwvlieghe; Bart J A Rijnders; Nele Philips; Rosanne Verwijs; Lore Vanderbeke; Carla Van Tienen; Katrien Lagrou; Paul E Verweij; Frank L Van de Veerdonk; Diederik Gommers; Peter Spronk; Dennis C J J Bergmans; Astrid Hoedemaekers; Eleni-Rosalina Andrinopoulou; Charlotte H S B van den Berg; Nicole P Juffermans; Casper J Hodiamont; Alieke G Vonk; Pieter Depuydt; Jerina Boelens; Joost Wauters Journal: Lancet Respir Med Date: 2018-07-31 Impact factor: 30.700
Authors: Joost Wauters; Ingrid Baar; Philippe Meersseman; Wouter Meersseman; Karolien Dams; Rudi De Paep; Katrien Lagrou; Alexander Wilmer; Philippe Jorens; Greet Hermans Journal: Intensive Care Med Date: 2012-08-16 Impact factor: 17.440
Authors: Waleed Alhazzani; Morten Hylander Møller; Yaseen M Arabi; Mark Loeb; Michelle Ng Gong; Eddy Fan; Simon Oczkowski; Mitchell M Levy; Lennie Derde; Amy Dzierba; Bin Du; Michael Aboodi; Hannah Wunsch; Maurizio Cecconi; Younsuck Koh; Daniel S Chertow; Kathryn Maitland; Fayez Alshamsi; Emilie Belley-Cote; Massimiliano Greco; Matthew Laundy; Jill S Morgan; Jozef Kesecioglu; Allison McGeer; Leonard Mermel; Manoj J Mammen; Paul E Alexander; Amy Arrington; John E Centofanti; Giuseppe Citerio; Bandar Baw; Ziad A Memish; Naomi Hammond; Frederick G Hayden; Laura Evans; Andrew Rhodes Journal: Intensive Care Med Date: 2020-03-28 Impact factor: 17.440
Authors: A Oliva; G Ceccarelli; C Borrazzo; M Ridolfi; G D 'Ettorre; F Alessandri; F Ruberto; F Pugliese; G M Raponi; A Russo; A Falletta; C M Mastroianni; M Venditti Journal: Infection Date: 2021-05-26 Impact factor: 3.553